i3 Asset Accelerator
Innovation ● Inflection ● Impact
The fast track to life-saving discoveries
The i3 Asset Accelerator advances the development of nascent discoveries from the Mount Sinai Health System into groundbreaking technology to help the global patient population. The i3 Asset Accelerator (or “i3”) stands for innovation, inflection and impact, the three ingredients necessary for a fast track to commercializing relevant inventions, transforming an emerging research idea into a mature, commercial-ready technology. Researchers will collaborate with MSIP to develop a project strategy ensuring that the most promising technologies advance beyond the lab bench to make an impact on human health.
The i3 Asset Accelerator aims to increase the pace of commercialization for a promising technology through strategic and milestone-driven investment.
Mount Sinai has established i3 with an initial investment of $10M over 4 years. The goal of i3 is to advance nascent discoveries by providing capital and business development support to reach well-defined inflection points, increase commercial value, and create an asset that can be licensed to industry or be the foundation of a startup company. All funded projects will have a milestone-based development plan and a clear path to commercialization, ensuring that i3 will advance projects with targeted goals. The key goals are to:
- rapidly generate commercially relevant intellectual property (IP), data, and results that substantially de-risk Mount Sinai assets.
- accelerate licensing to existing corporations or Mount Sinai startups funded by professional investors.
- secure additional funding from an industry partner or an investor to further advance the development of the asset.
All funded projects will be supervised by a dedicated program manager with support from advisors from the pharmaceutical and biotech sectors, venture capitalists, entrepreneurs, biomedical research experts, and leaders from the Mount Sinai community. i3 offers the support and resources needed to ensure each participating technology reaches its full, patent-ready potential.
Funding will be applied on a milestone-basis, will continue after each milestone is successfully achieved, and may be terminated at any time. Projects that are between 6 to 20 months in duration are desired.
Preference will be given to projects performed by validated third-party service providers including contract research organizations (CROs), engineering and prototyping firms, and software developers.